Comprehensive Analysis of Expression and Prognostic Value of Sirtuins in Ovarian Cancer

Overview

Journal Front Genet

Date 2019 Oct 2

PMID 31572453

Citations 11

Authors

Xiaodan Sun

Shouhan Wang

Qingchang Li

Affiliations

Soon will be listed here.

Abstract

Sirtuins (SIRTs) 1-7 are a family of intracellular enzymes, which possess nicotinamide adenine dinucleotide-dependent deacetylase activity. Emerging evidence suggest that SIRTs play vital roles in tumorigenesis by regulating energy metabolism, DNA damage repair, genome stability, and other cancer-associated cellular processes. However, the distinct roles of the seven members in ovarian cancer (OC) remain elusive. The transcriptional expression patterns, prognostic values, and genetic alterations of seven SIRTs in OC patients were investigated in this study using a range of databases: Oncomine and Gene Expression Profiling Interactive Analysis, Kaplan-Meier plotter, the Cancer Genome Atlas, and cBioPortal. The protein-protein interaction networks of SIRTs were assessed in the String database. Gene Ontology enrichment and Kyoto Encyclopedia of Genes and Genomes pathway were analyzed in Database for Annotation, Visualization, and Integrated Discovery. The mRNA expression levels of SIRT1-4 and 7 were downregulated, while that of SIRT5 was upregulated and SIRT6 exhibited both expression dysregulation in patients with OC. Dysregulated SIRTs mRNA expression levels were associated with prognosis. Moreover, genetic alterations primarily occurred in SIRT2, 5, and 7. Network analysis indicated that SIRTs and their 20 interactors were associated with tumor-related pathways. This comprehensive bioinformatics analysis revealed that SIRT1-4, 6, and 7 may be new prognostic biomarkers, while SIRT5 is a potential target for accurate therapy for patients with OC, but further studies are needed to confirm this notion. These findings will contribute to a better understanding of the distinct roles of SIRTs in OC.

Citing Articles

Emerging roles of mitochondrial sirtuin SIRT5 in succinylation modification and cancer development.

Ke Z, Shen K, Wang L, Xu H, Pan X, Qian Z Front Immunol. 2025; 16:1531246.

PMID: 39944690 PMC: 11814216. DOI: 10.3389/fimmu.2025.1531246.

SIRT5 participates in the suppressive tumor immune microenvironment of EGFR-mutant LUAD by regulating the succinylation of ACAT1.

Shouhan W, Qingchang L, Xiaodan S Heliyon. 2024; 10(21):e39743.

PMID: 39524872 PMC: 11543872. DOI: 10.1016/j.heliyon.2024.e39743.

A nanoscale natural drug delivery system for targeted drug delivery against ovarian cancer: action mechanism, application enlightenment and future potential.

Li Y, Shen Q, Feng L, Zhang C, Jiang X, Liu F Front Immunol. 2024; 15:1427573.

PMID: 39464892 PMC: 11502327. DOI: 10.3389/fimmu.2024.1427573.

Investigating the effects of PTEN mutations on cGAS-STING pathway in glioblastoma tumours.

Dogan E, Yildirim Z, Akalin T, Ozgiray E, Akinturk N, Aktan C J Neurooncol. 2024; 166(2):283-292.

PMID: 38214828 PMC: 10834568. DOI: 10.1007/s11060-023-04556-4.

LINC01234 regulates microRNA-27b-5p to induce the migration, invasion and self-renewal of ovarian cancer stem cells through targeting SIRT5.

Ke F, Ren C, Zhai Z, Gao X, Wei J, Zhu Y Cell Cycle. 2022; 21(10):1020-1033.

PMID: 35230909 PMC: 9037434. DOI: 10.1080/15384101.2022.2040282.

References

Aljada A, Saleh A, Alkathiri M, Shamsa H, Al-Bawab A, Nasr A . Altered Sirtuin 7 Expression is Associated with Early Stage Breast Cancer. Breast Cancer (Auckl). 2015; 9:3-8. PMC: 4396534. DOI: 10.4137/BCBCR.S23156. View

Wang H, Lu R, Xie S, Zheng H, Wen X, Gao X . SIRT7 Exhibits Oncogenic Potential in Human Ovarian Cancer Cells. Asian Pac J Cancer Prev. 2015; 16(8):3573-7. DOI: 10.7314/apjcp.2015.16.8.3573. View

Tan M, Peng C, Anderson K, Chhoy P, Xie Z, Dai L . Lysine glutarylation is a protein posttranslational modification regulated by SIRT5. Cell Metab. 2014; 19(4):605-17. PMC: 4108075. DOI: 10.1016/j.cmet.2014.03.014. View

Tang Z, Li C, Kang B, Gao G, Li C, Zhang Z . GEPIA: a web server for cancer and normal gene expression profiling and interactive analyses. Nucleic Acids Res. 2017; 45(W1):W98-W102. PMC: 5570223. DOI: 10.1093/nar/gkx247. View

Barber M, Michishita-Kioi E, Xi Y, Tasselli L, Kioi M, Moqtaderi Z . SIRT7 links H3K18 deacetylation to maintenance of oncogenic transformation. Nature. 2012; 487(7405):114-8. PMC: 3412143. DOI: 10.1038/nature11043. View

von Mering C, Huynen M, Jaeggi D, Schmidt S, Bork P, Snel B . STRING: a database of predicted functional associations between proteins. Nucleic Acids Res. 2003; 31(1):258-61. PMC: 165481. DOI: 10.1093/nar/gkg034. View

Bonome T, Levine D, Shih J, Randonovich M, Pise-Masison C, Bogomolniy F . A gene signature predicting for survival in suboptimally debulked patients with ovarian cancer. Cancer Res. 2008; 68(13):5478-86. PMC: 7039050. DOI: 10.1158/0008-5472.CAN-07-6595. View

OCallaghan C, Vassilopoulos A . Sirtuins at the crossroads of stemness, aging, and cancer. Aging Cell. 2017; 16(6):1208-1218. PMC: 5676072. DOI: 10.1111/acel.12685. View

Du J, Zhou Y, Su X, Yu J, Khan S, Jiang H . Sirt5 is a NAD-dependent protein lysine demalonylase and desuccinylase. Science. 2011; 334(6057):806-9. PMC: 3217313. DOI: 10.1126/science.1207861. View

10.

Huang D, Sherman B, Lempicki R . Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc. 2009; 4(1):44-57. DOI: 10.1038/nprot.2008.211. View

11.

. Integrated genomic analyses of ovarian carcinoma. Nature. 2011; 474(7353):609-15. PMC: 3163504. DOI: 10.1038/nature10166. View

12.

Aljada A, Saleh A, Al Suwaidan S . Modulation of insulin/IGFs pathways by sirtuin-7 inhibition in drug-induced chemoreistance. Diagn Pathol. 2014; 9:94. PMC: 4229859. DOI: 10.1186/1746-1596-9-94. View

13.

Nakagawa T, Lomb D, Haigis M, Guarente L . SIRT5 Deacetylates carbamoyl phosphate synthetase 1 and regulates the urea cycle. Cell. 2009; 137(3):560-70. PMC: 2698666. DOI: 10.1016/j.cell.2009.02.026. View

14.

Bell E, Emerling B, Ricoult S, Guarente L . SirT3 suppresses hypoxia inducible factor 1α and tumor growth by inhibiting mitochondrial ROS production. Oncogene. 2011; 30(26):2986-96. PMC: 3134877. DOI: 10.1038/onc.2011.37. View

15.

Zhang J, Yin X, Xu C, Ning Y, Chen M, Zhang H . The histone deacetylase SIRT6 inhibits ovarian cancer cell proliferation via down-regulation of Notch 3 expression. Eur Rev Med Pharmacol Sci. 2015; 19(5):818-24. View

16.

Finley L, Carracedo A, Lee J, Souza A, Egia A, Zhang J . SIRT3 opposes reprogramming of cancer cell metabolism through HIF1α destabilization. Cancer Cell. 2011; 19(3):416-28. PMC: 3065720. DOI: 10.1016/j.ccr.2011.02.014. View

17.

Qin J, Liu Y, Lu Y, Liu M, Li M, Li J . Hypoxia-inducible factor 1 alpha promotes cancer stem cells-like properties in human ovarian cancer cells by upregulating SIRT1 expression. Sci Rep. 2017; 7(1):10592. PMC: 5587562. DOI: 10.1038/s41598-017-09244-8. View

18.

Osborne B, Bentley N, Montgomery M, Turner N . The role of mitochondrial sirtuins in health and disease. Free Radic Biol Med. 2016; 100:164-174. DOI: 10.1016/j.freeradbiomed.2016.04.197. View

19.

Dryden S, Nahhas F, Nowak J, Goustin A, Tainsky M . Role for human SIRT2 NAD-dependent deacetylase activity in control of mitotic exit in the cell cycle. Mol Cell Biol. 2003; 23(9):3173-85. PMC: 153197. DOI: 10.1128/MCB.23.9.3173-3185.2003. View

20.

Shuang T, Wang M, Zhou Y, Shi C . Over-expression of Sirt1 contributes to chemoresistance and indicates poor prognosis in serous epithelial ovarian cancer (EOC). Med Oncol. 2015; 32(12):260. DOI: 10.1007/s12032-015-0706-8. View